Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04853940
Other study ID # 419/20
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date January 1, 2022

Study information

Verified date March 2022
Source Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Further knowledge regarding sequelae in severe COVID-19 patients who have required ICU admission for invasive mechanical ventilation is still needed. Available evidence suggests ongoing respiratory impairment and impact in quality of life.


Description:

PURPOSE: To evaluate post-ICU clinical outcomes in severe COVID-19 ICU survivors. DESIGN: A prospective observational study conducted in public hospital in Madrid, Spain. METHODS: Participants: patients diagnosed with severe COVID-19 who have survived ICU admission for invasive mechanical ventilation and have been discharged from hospital. Intervention: Patients will be invited to attend follow-up visits at the hospital for assessments 3 months and 6 months after ICU discharge. Outcome measures: Tests of respiratory muscles function will include ultrasonography of the diaphragm muscle to measure diaphragm thickness (DT), diaphragm thickening ratio (TR) and diaphragm excursion (DE); respiratory muscle strength measurement to obtain Maximal Inspiratory Pressure (MIP), Maximal Expiratory Pressure (MEP) and Maximal Sniff Nasal Inspiratory Pressure (SNIP); functional exercise capacity will be assessed with the Six Minutes Walk Test (6MWT); dyspnea and health-related quality of life will be evaluated with the Modified Medical Research Council Scale (mMRC Scale) and the Saint George's Respiratory Questionnaire (SGRQ). Data on participants' demographics and clinical data will also be collected. Statistical Analysis: Descriptive statistics will be used to summarise data. Spearman's correlation coefficients will be used to explore associations between variables. CONCLUSIONS AND SIGNIFICANCE OF THE RESEARCH: Understanding post-ICU clinical outcomes in patients with severe COVID-19 may help develop future prevention, therapeutic and follow-up strategies that improve quality of care and outcomes


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 1, 2022
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ?18 years old, - subjects diagnosed with COVID-19 confirmed by positive SARS-CoV-2 PCR testing who require admission to ICU for invasive mechanical ventilation - invasive ventilation > 24 hours. Exclusion Criteria: - pre-existing cognitive impairment, - communication/language barrier - any concurrent physical or mental health condition/ impairment that prevents subjects from taking part in evaluations or providing informed consent - loss of independent walking ability (with or without walking aids) prior to hospitalisation defined by a score of =2 on the mobility item of the modified Barthel Index, - pregnancy, - any injuries/surgery that requires medical bed rest.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data collection and clinical testing of subjects
6-months follow-up with clinical testing at 3 and 6 months

Locations

Country Name City State
Spain ICU. Ramón y Cajal University Hospital Madrid

Sponsors (1)

Lead Sponsor Collaborator
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal Inspiratory Pressure (MIP) (centimetres of water, cmH20) It is the greater pressure which may be generated during maximal inspiration by the inspiratory muscles. < 3 months after ICU discharge
Primary Maximal Inspiratory Pressure (MIP) (centimetres of water, cmH20) It is the greater pressure which may be generated during maximal inspiration by the inspiratory muscles. within 6 months after ICU discharge
Secondary Diaphragm Thickening Ratio during deep breathing (centimetres) B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio during deep breathing. Diaphragm Thickening Ratio = Diaphragm Thickness at Functional Residual Capacity/ Diaphragm thickness at Total Lung Capacity. within 3 months after ICU discharge
Secondary Diaphragm Thickening Ratio during deep breathing (centimetres) B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio during deep breathing. Diaphragm Thickening Ratio = Diaphragm Thickness at Functional Residual Capacity/ Diaphragm thickness at Total Lung Capacity. within 6 months after ICU discharge
Secondary Diaphragm Thickening Ratio during quiet breathing (centimetres) B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio at Tidal Volume. Diaphragm Thickening Ratio = Diaphragm Thickness at the end of a quiet expiration/ Diaphragm thickness at the end of a quiet inspiration. within 3 months after ICU discharge
Secondary Diaphragm Thickening Ratio during quiet breathing (centimetres) B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio at Tidal Volume. Diaphragm Thickening Ratio = Diaphragm Thickness at the end of a quiet expiration/ Diaphragm thickness at the end of a quiet inspiration. within 6 months after ICU discharge
Secondary Diaphragm Excursion during deep breathing (centimetres) M-mode Diaphragm Ultrasound imaging will be performed to measure diaphragm excursion during deep breathing defined as the displacement (centimetres) of the diaphragm between Functional Residual Capacity and Total Lung Capacity within 3 months after ICU discharge
Secondary Diaphragm Excursion during deep breathing (centimetres) M-mode Diaphragm Ultrasound imaging will be performed to measure diaphragm excursion during deep breathing defined as the displacement (centimetres) of the diaphragm between Functional Residual Capacity and Total Lung Capacity. within 6 months after ICU discharge
Secondary Maximal Expiratory Pressure (MEP) (cmH20) It is the greater pressure which may be generated during maximal expiration by the inspiratory muscles. within 3 months after ICU discharge
Secondary Maximal Expiratory Pressure (MEP) (cmH20) It is the greater pressure which may be generated during maximal expiration by the inspiratory muscles. within 6 months after ICU discharge
Secondary Modified Medical Research Council (mMRC) Dyspnea score Dyspnea will be measured with the mMRC Dyspnea scale (range: 0-4, higher values indicating higher level of dyspnea) within 3 months following ICU discharge
Secondary Modified Medical Research Council (mMRC) Dyspnea score Dyspnea will be measured with the mMRC Dyspnea scale (range: 0-4, higher values indicating higher level of dyspnea) within 6 months following ICU discharge
Secondary 6-Minutes Walk Test (6MWT) (metres) The 6MWT will be used to measure exercise capacity within 3 months following ICU discharge
Secondary 6-Minutes Walk Test (6MWT) (metres) The 6MWT will be used to measure exercise capacity within 6 months following ICU discharge
Secondary Saint George's Respiratory Questionnaire (SGRQ) score The SGRQ is used to measure health-related quality of life (range: 0-100, higher scores represent higher impairment in quality of life) within 3 months following ICU dischargemonths following ICU discharge
Secondary Saint George's Respiratory Questionnaire (SGRQ) score The SGRQ is used to measure health-related quality of life (range: 0-100, higher scores represent higher impairment in quality of life) within 6 months following ICU dischargemonths following ICU discharge
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3